Document is current
Any future updates will be listed below
-
Authors
Sreeram, Aravind
Stroobant, Emily E.
Laszkowska, Monika
Guilford, Parry
Shimada, Shoji
Nishimura, Makoto
Shah, Sohrab
Vardhana, Santosha
Tang, Laura H.
Strong, Vivian E.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
- License Information
-
More Information
Article History
Received: 7 May 2024
Accepted: 16 August 2024
First Online: 29 September 2024
Disclosure
: Monika Laszkowska reports grants/contracts from AI Medical Service. Parry Guilford reports consulting fees from Pacific Edge Ltd., scientific advisory board roles for No Stomach for Cancer and the De Gregorio Family Foundation, and stock/stock options from Pacific Edge Ltd. Makoto Nishimura reports consulting for Boston Scientific, Olympus America, Nora medical, Fujifilm, and AI Medical. Sohrab Shah reports grants/contracts from AstraZeneca and Bristol Meyers Squibb and a leadership role in the Genome Canada Scientific Advisory Council. Santosha Vardhana reports grants/contracts from Bristol Meyers Squibb. Vivian E. Strong reports a one-time speaking honorarium from AstraZeneca and one-time consultation for Regeneron. Aravind Sreeram, Emily E. Stroobant, Shoji Shimada, and Laura H. Tang report no relationships with outside entities. This study was funded in part by the NIH/NCI Cancer Center Support Grant (P30 CA008748), which supports the institution’s core resources.
